International Journal of Pharmacy
Journal Homepage: http://www.pharmascholars.com

Short Communication **CODEN: IJPNL6**

The Role of Toxicology in Public Health-Assessing Chemical Risks

Karl Walter*

Department of Pharmacy, University of Durban, Durban, South Africa

***Corresponding author email**: Walterkarloson12@hotmail.com

Received: *15-Apr-2024, Manuscript No. IJP-24-137593;* ***Editor assigned:*** *18-Apr-2024, PreQC No. IJP-24-137593 (PQ);* ***Reviewed:*** *02-May-2024, QC No. IJP-24-137593;* ***Revised:*** *09-May-2024, Manuscript No. IJP-24-137593 (R);* ***Published:*** *16-May-2024, DOI:10.37522/2249-1848.2024.14(3).105*

ABOUT THE STUDY

Toxicology is the scientific study of the adverse effects of chemical substances on living organisms. It plays an important role in identifying potential hazards and understanding the mechanisms of toxicity. The field encompasses various sub-disciplines, including environmental toxicology, forensic toxicology, clinical toxicology, and regulatory toxicology, each focusing on different aspects of chemical exposure and its implications on health and the environment.

Fundamentals of toxicology

Cholesterol management elevated levels of cholesterol, particularly Low-Density Lipoprotein (LDL), are a major risk factor for atherosclerosis, a condition characterized by the buildup of plaque in the arteries [1]. Statins, a class of drugs primarily used to lower cholesterol levels, have demonstrated significant efficacy in reducing the risk of cardiovascular events. By inhibiting the enzyme HMG-CoA reductase, statins decrease the production of cholesterol in the liver, thereby lowering LDL levels and attenuating atherosclerotic progression.

Moreover, statins exhibit pleiotropic effects, including anti-inflammatory and endothelial function improvement, further contributing to their cardio protective properties [2]. At its core, toxicology seeks to answer three fundamental questions.

- What are the harmful effects of a substance?
- How are these effects induced?
- Under what conditions do these effects occur?

Antiplatelet agents

The dose-response relationship is a foundation concept in toxicology. It asserts that the magnitude of toxic effect is directly related to the dose of the substance: The dose makes the poison [3]. This means that almost any substance can be harmful at a sufficientl high dose, while even highly toxic substances may be harmless at low doses [4].

Mechanisms of toxicity

Toxic agents can exert their effects through various mechanisms:

Direct toxicity: Substances can cause cell damage or death by interacting with cellular components.

Biochemical toxicity: Chemicals may interfere with biochemical pathways, leading to metabolic imbalances.

Geno-toxicity: Some agents can damage genetic material, potentially causing mutations and cancer.

Immuno-toxicity: Chemicals may affect the immune system, either by suppressing it or triggering hypersensitivity reactions.

Risk assessment in toxicology

Risk assessment is a systematic process used to evaluate the potential health risks posed by chemical exposures. It integrates toxicological data with exposure information to estimate the likelihood and severity of adverse health outcomes [5]. The process comprises four key steps:

Hazard identification: This step involves determining whether a chemical is inherently capable of causing harm. It relies on data from laboratory animal studies, epidemiological research, and other scientific sources [6].

Dose-response assessment: Here, the relationship between the dose of a chemical and the extent of the toxic effect is quantified. This often involves extrapolating data from high-dose animal studies to predict human health effects at lower exposure levels [7].

Exposure assessment: This step characterizes the nature and magnitude of human exposure to the chemical. It considers various exposure routes (e.g., inhalation, ingestion, and dermal contact), duration, and frequency of exposure in different populations [8].

Risk characterization: The final step integrates data from the previous steps to estimate the overall risk. It combines the likelihood of exposure with the potential for harm to provide comprehensive risk profile [9,10].

Challenges in risk assessment

Several challenges complicate the risk assessment process:

Uncertainty and variability: Inherent uncertainties in extrapolating animal data to humans, variations in individual susceptibility, and differences in exposure scenarios introduce complexity [11].

Chemical mixtures: Humans are often exposed to multiple chemicals simultaneously, but risk assessments typically focus on single substances.

Emerging contaminants: New chemicals and previously unrecognized toxicants continuously emerge, necessitating ongoing research and updated risk assessments [12].

Regulatory toxicology and public health

Regulatory toxicology is critical in translating scientific findings into policies that protect public health [13]. Regulatory agencies such as the Environmental Protection Agency (EPA) in the United States and the European Chemicals Agency (ECHA) in the European Union use risk assessment data to establish safety standards exposure limits, and guidelines for chemical use and disposal [14]. For example, the EPA conducts risk assessments for pesticides to ensure that they do not pose unreasonable risks to human health or the environment when used according to label instructions. Similarly, the FDA assesses the safety of food additives, pharmaceuticals, and cosmetics to ensure they meet stringent safety criteria before they can be marketed [15].

CONCLUSION

Toxicology and risk assessment are integral components of public health and environmental protection. By understanding the toxic properties of chemicals and assessing the risks associated with exposure, scientists and regulators can make informed decisions to mitigate potential hazards. Despite the challenges, ongoing advancements in toxicological research and risk assessment methodologies continue to enhance our ability to safeguard health and the environment in an increasingly complex chemical landscape.

REFERENCES

1. Weaver RJ, Valentin JP. Today's challenges to de-risk and predict drug safety in human "Mind-the-Gap". *Toxicol Sci*. 2019;167(2):307-321.
2. Moggs J, Moulin P, Pognan F, et al. Investigative safety science as a competitive advantage for pharma. *Expert Opin Drug Metab Toxicol*. 2012;8(9):1071-1082.
3. Beilmann M. Optimizing drug discovery by investigative toxicology: Current and future trends. *ALTEX*. 2019;36(2):289-313.
4. Roberts RA. Understanding drug targets: No such thing as bad news. *Drug Discov Today*. 2018;23(12):1925-1928.
5. Favuzza P, de Lera Ruiz M, Thompson JK, et al. Dual plasmepsin-targeting antimalarial agents disrupt multiple stages of the malaria parasite life cycle. *Cell Host Microbe*. 2020;27:642-658.
6. Zuhl AM, Nolan CE, Brodney MA, et al. Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of beta-secretase inhibitors. *Nat Commun.* 2016;7:13042.
7. Barber J, Sikakana P, Sadler C, et al. A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria. *Toxicol Res.* 2021;10(2):203-213.
8. Siintola E. Cathepsin D deficiency underlies congenital humanneuronalceroidlipofuscinosis. *Brain.* 2006;129:1438-1445.
9. Ramirez-Montealegre D, Rothberg PG, Pearce DA. Another disorder finds its gene. *Brain.* 2006;129(6):1353-1356.
10. Hornberg JJ. Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies. *Drug Discov Today.* 2014;19:1137-1144.
11. Hornberg JJ. Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how. *Drug Discov Today.* 2014;19:1131-1136.
12. Atienzar FA. Predictivity of dog co-culture model, primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humans. *Toxicol Appl Pharm.* 2014;275:44-61.
13. Atienzar F. Investigative safety strategies to improve success in drug development. *J Med Dev Sci.* 2016;2:2-29.
14. Lin ZW, Will Y. Evaluation of drugs with specific organ toxicities in organ-specific cell lines. *Toxicol. Sci.* 2012;126:114-127.
15. Langhans SA. Three-dimensional *in vitro* cell culture models in drug discovery and drug repositioning. *Front Pharmacol.* 2018;9:6.